Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 1/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941271 | 1.00 | EGFR (1.00) | EGFRABCG2ERBB2AURKBCLK4 | |
| Hydrochloric Acid SCHEMBL20856873 | 0.98 | EGFR (0.96) | EGFRABCG2ERBB2AURKBCLK4 | |
| Hydrochloric Acid SCHEMBL29394578 | 0.98 | EGFR (0.96) | EGFRABCG2ERBB2AURKBCLK4 | |
| Hydrochloric Acid SCHEMBL8808235 | 0.95 | EGFR (0.90) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL5569376 | 0.90 | EGFR (0.81) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL8976752 | 0.88 | EGFR (0.78) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL6823372 | 0.87 | EGFR (0.77) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL5569016 | 0.86 | EGFR (0.75) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL5569041 | 0.86 | EGFR (0.75) | EGFRABCG2ERBB2AURKBCLK4 | |
| SCHEMBL14027230 | 0.86 | EGFR (0.75) | EGFRABCG2ERBB2AURKBCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | claimed |
| WO-2025007166-A1 | BCR-ABL INHIBITORS FOR USE IN TREATING KELOID DISEASE | UNIVERSITY OF CAPE TOWN (ZA) | 2025-01-02 | — | — | WO | claimed |
| CN-118834200-A | 4-Anilino quinazoline compound containing amide structure and application thereof | 辽宁大学 | 2024-10-25 | — | — | CN | claimed |
| CN-114437161-B | Zidovudine spliced 4-aniline quinazoline compound and preparation method and application thereof | 遵义医药高等专科学校 | 2023-09-12 | — | — | CN | claimed |
| CN-114437046-B | 5-fluorouracil spliced 4-aniline quinazoline compound and preparation method and application thereof | 遵义医药高等专科学校 | 2023-09-12 | — | — | CN | claimed |
| CN-109942500-B | Preparation of rhein anilino quinazoline derivatives and anti-tumor application | 广西医科大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114437161-A | Zidovudine spliced 4-aniline quinazoline compound as well as preparation method and application thereof | 遵义医药高等专科学校 | 2022-05-06 | — | — | CN | claimed |
| CN-114437046-A | 5-fluorouracil spliced 4-aniline quinazoline compound and preparation method and application thereof | 遵义医药高等专科学校 | 2022-05-06 | — | — | CN | claimed |
| EP-3908577-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-11-17 | — | — | EP | claimed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | claimed |
| US-20040242854-A1 | Chemical capture reagent | GE HEALTHCARE UK LIMITED (GB) | 2004-12-02 | — | — | US | claimed |
| WO-2004098612-A2 | CALCITRIOL ANALOGS OF USES THEREOF | AB SCIENCE (FR) | 2004-11-18 | — | — | WO | claimed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| EP-1411993-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-28 | — | — | EP | claimed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | claimed |
| US-6562319-B2 | 4-(phenylamino)quinazolines | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-05-13 | — | — | US | claimed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | claimed |
| WO-2002073235-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-19 | — | — | WO | claimed |
| US-20020128553-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. | 2002-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128553-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885ABCG2 710/4885ERBB2 2/4885 |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | EGFR, PTGFR, ERBB2 | EGFR 1/4885ABCG2 2973/4885ERBB2 3/4885 |
| US-20040242854-A1 | Chemical capture reagent | SPPL2B, PRXL2A, PLG | EGFR 440/4885ABCG2 1345/4885ERBB2 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.